Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma
Journal of Cancer Research & Clinical Oncology, 07/17/2012
D’Souza SS et al. – This first demonstration of beneficial angiopoietin–2 inhibition in neuroblastoma offers an additional approach for future therapy strategies, especially by using L1–10 in the setting of minimal residual disease.



